The economical impact of dementia;Impact économique de la démence

Presse Medicale

Volumn 34, Issue 1, 2005, Pages 35-41

  Bonin Guillaume, Sylvie ^a   Zekry, Dina ^b   Giacobini, Ezio ^b   Gold, Gabriel ^b   Michel, Jean Pierre ^b  

^a HÔPITAL NORD   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DRUG COST; HEALTH CARE COST; HEALTH CARE FINANCING; HUMAN; LONG TERM CARE; REVIEW;

EID: 12544250350     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)83882-5     Document Type: Review

References (54)

1. Souêtre E, Qing W, Vigoureux I. Economic analysis of Alzheimer's disease in outpatients: impact of symptom severity. Alzheimer's disease: therapeutic strategies. Giacobini E, Becker R, Birkhauser, Boston 1994: 470-80.
2. Kalache A. Ageing world-wide. Epidemiology in old age. Ebrahim S, Kalache A. British Medical Society Publishing Group, London 1996: 22-31.
3. Khachaturian ZS, Radebaugh TS. Alzheimer disease: where are we now? Where are we going? Alzheimer Dis Assoc Disord 1998; 12 (Suppl. 3): S24-8.
4. Ritchie K, Kildea D. Is senile dementia "age-related" or "ageing-related"? Evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 1995; 346: 931-4.
5. Herrmann F, Mermod JJ, Henderson S, Michel J. Epidemiology of dementia in Geneva. Management of Aging. Michel JPH. The University of Geneva Experience. Karger, Basel 1999: 94-100.
6. Ramaroson H, Helmer C, Barberger-Gateau P, Letenneur L, Dartigues JF. Prevalence of dementia and Alzheimer's disease among subjects aged 75 years or over: updated results of the PAQUID cohort. Rev Neurol (Paris) 2003; 159: 405-11.
7. Dartigues JF, Helmer C, Dubois B, Duyckaerts C, Laurent B, Pasquier F et al. Alzheimer's disease: a public health problem: yes, but a priority? Rev Neurol (Paris) 2002; 158: 311-15.
8. Dartigues JF, Gagnon M, Barberger-Gateau P, Letenneur L, Commenges D, Sauvel C. The Paquid epidemiological program on brain ageing. Neuroepidemiology 1992; 11 Suppl 1: 14-18.
9. Murray C, Lopez A. Summary: the global burden of disease. Cambridge Mass.: Harvard University Press, 1997.
10. Henderson A, Jorm A. Definition, and epidemiology of dementia. Maj M, Sartorius N. Dementia. Chichester: John Willey & sons, LTD, 2000: 1-33.
11. Tabo A, Nubukpo P, Clément J, Thomas P. État actuel des connaissances sur la démence en Afrique subsaharienne. Rev Geriatrie 2003; 28: 803-6.
12. Whitehouse PJ. Pharmacoeconomics of dementia. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 5): S22-32; discussion S32-3
13. Sternberg SA, Wolfson C, Baumgarten M. Undetected dementia in community-dwelling older people: the Canadian Study of Health and Aging. J Am Geriatr Soc 2000; 48: 1430-4.
14. Wimo A, Karlson G, Jonsson B, Winblad B. The Health Economics of dementia. Jonhn Wiley & Son, London 1998.
15. Bloom BS, de Pouvourville N, Straus WL. Cost of illness of Alzheimer's disease: how useful are current estimates? Gerontologist 2003; 43: 158-64.
16. Winblad B, Hill S, Beermann B, Post SG, Wimo A. Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997; 11 Suppl 3: 39-45.
17. Wimo A, Ljunggren G, Winblad B. Costs of dementia and dementia care: a review. Int J Geriatr Psychiatry 1997; 12: 841-56.
18. Volz A, Monsch A, Zahno A, Wettstein A, Stähelin H, Grünig R. Was kostete die Schweiz die Alzheimer-Krankheit 1998? Eine präliminäre Analyse. Praxis Schweiz Rundschau Med 2000; 89: 803-11.
19. Meerding WJ, Bonneux L, Polder JJ, Koopmanschap MA, van der Maas PJ. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. Br Med J 1998; 317: 111-15.
20. Ernst RL, Hay JW. Economic research on Alzheimer disease: a review of the literature. Alzhiemer Dis Assoc Disord 1997; 11 Suppl 6: 135-45.
21. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994; 84: 1261-4.
22. Fagnani E, Everhard F, Buteau L, Detournay B, Sourgen C, Dartigues J. Coût et retentissement de la maladie d'Alzheimer en France: une extrapolation des données de l'étude Paquid. Rev Geriatrie 1999; 24: 205-11.
23. Schumock GT. Economic considerations in the treatment and management of Alzheimer's disease. Am J Health Syst Pharm 1998; 55 (Suppl. 2): S17-21.
24. Gutterman EM, Markowitz JS, Lewis B, Fillit H. Cost of Alzheimer's disease and related dementia in managed-medicare. J Am Geriatr Soc 1999; 47: 1065-71.
25. Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care 1999; 37: 27-32.
26. Souetre EJ, Qing W, Vigoureux I, Dartigues JF, Lozet H, Lacomblez L et al. Economic analysis of Alzheimer's disease in outpatients: impact of symptom severity. Int Psychogeriatr 1995; 7: 115-22.
27. Rigaud AS, Fagnani F, Bayle C, Latour F, Traykov L, Forette F. Patients with Alzheimer's disease living at home in France: costs and consequences of the disease. V Geriatr Psychiatry Neurol 2003; 16: 140-5.
28. Joël M. Le coût de la maladie d'Alzheimer: un probème économique délicat. Médecine/Sciences 2002; 18: 757-9.
29. Drummond M, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford 1987.
30. Andrieu S, Balardy L, Gillette-Guyonnet S, Bocquet H, Cantet C, Albarede JL et al. Burden experienced by informal caregivers assisting Alzheimer's patients in the REAL. FR study. Rev Med Interne 2003; 24 (Suppl. 3): 351s-9s.
31. Joël M, Gramain A, Cozette E, Colvez A. Situation économique et qualité de vie des aidants aux malades atteints de démence sénile de type Alzheimer. Revue Economique, Les enjeux éonomiques du financement des retraites 2000; 51 (Hors série février): 163-84.
32. Trabucchi M. An economic perspective on Alzheimer's disease. J Geriatr Psychiatry Neurol 1999; 12: 29-38.
33. Albert SM, Sano M, Bell K, Merchant C, Small S, Stern Y. Hourly care received by people with Alzheimer's disease: results from an urban, community survey. Gerontologist 1998; 38(6): 704-14.
34. Fox PJ. Service use and cost outcomes for persons with Alzheimer disease. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 6): 125-34.
35. Knapp M, Wilkinson D, Wigglesworth R. The economic consequences of Alzheimer's disease in the context of new drug developments. Int J Geriatr Psychiatry 1998; 13: 531-43.
36. Gonthier R, Terrat CCG. Comment faire évoluer la perception de la démence du sujet âgé en médecine géné rale. Rev Gériatrie 2001; 26: 445-6.
37. Barberger-Gateau P, Commenges D, Gagnon M, Letenneur L, Sauvel C, Dartigues JF. Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. J Am Geriatr Soc 1992; 40: 1129-34.
38. Robert PH, Schuck S, Dubois B, Olie JR, Lepine JP, Gallarda T et al. Screening for Alzheimer's disease with the short cognitive evaluation battery. Dement Geriatr Cogn Disord 2003; 15: 92-8.
39. Trabucchi M, Govoni S, Bianchetti A. Socio-economic aspects of Alzheimer's disease treatment. Alzheimer's disease: therapeutic strategies. Giacobini E, Becker R. Birkhauser, Boston 1994: 459-63.
40. Trabucchi M, Ghisla K, Bianchetti A. CODEM: a longitudinal study on Alzheimer disease costs. Alzheimer's disease: from molecular biology to therapy. Giacobini E, Becker R. Birkhauser, Boston 1996: 561-5.
41. Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S. Relation between severity of Alzheimer's disease and costs of caring. Can Med Assoc J 1998; 159: 457-65.
42. Souetre E, Thwaites RM, Yeardley HL. Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease. Br J Psychiatry 1999; 174: 51-5.
43. Neumann PJ, Hermann RC, Berenbaum PA, Weinstein MC. Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease. Psychiatr Serv 1997; 48: 1440-4.
44. Busschbach JJ, Brouwer WB, van der Donk A, Passchier J, Rutten FF. An outline for a cost-effectiveness analysis of a drug for patients with Alzheimer's disease. Pharmacoeconomics 1998; 13(1 Pt 1): 21-34.
45. Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003; 21: 327-40.
46. Wimo A, Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003; 15(1): 44-54.
47. Fagnani F, Lafuma A, Pechevis M, Rigaud AS, Traykov L, Seux ML et al. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. Dement Geriatr Cogn Disord 2004; 17: 5-13.
48. Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock R. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 2003; 18: 740-7.
49. Ott BR, Lapane KL. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. J Am Geriatr Soc 2002; 50: 35-40.
50. Wolfson C, Oremus M, Shukla V, Monoli F, Demers L, Perrault A et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002; 24: 862-86; discussion 837.
51. Clegg A, Bryant J, Nicholson T, McIntyre L, DeBroes S, Gerard K et al. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review. Int J Technol Assess Health Care 2002; 18: 497-507.
52. Wimo A. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations. Drugs Aging 2004; 21: 279-95.
53. Clegg A, Bryant J, Nicholson T. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001; 5: 1-137.
54. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002; 59: 1721-9.